91 results about "Anxiety depression" patented technology

The present invention is a method for the treatment of eating disorders by nerve tissue stimulation and infusion techniques to one or more areas of the brain affecting hunger and satiety; palatability and aversion; hedonism; reward / addiction behavior; mood; anxiety; depression, taste and smell. The invention also comprises methods for the treatment of disorders of these individual behaviors and in particular, disorders of taste and / or smell.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3′, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.

The invention provides a probiotic composition and a preparation method and applications thereof, and belongs to the technical field of health-care foods. The probiotic composition comprises probiotics and prebiotics. The probiotics comprise lactobacillus acidophilus NCFM, lactobacillus rhamnosus HN001, lactic acid bacteria composite powder GI, lactic acid bacteria composite powder OH, bifidobacterium animalis B94, bifidobacterium bifidum R0071, lactobacillus casei R0215, live bacillus coagulans GBI30,6086 and lactobacillus rhamnosus GG. The prebiotics include fructo-oligosaccharides, resistant dextrins and lactitol. The mass ratio of the probiotics to the prebiotics is (300-350):(1300-1400). The total viable bacteria concentration of the probiotics in the probiotics composition is more than or equal to 9.0x10<9> CFU / g. The probiotic composition provided by the invention can obviously improve sleep quality, and significantly relieve anxiety and depression.

System, method and media for altering the mood of an occupant (such as a driver) of a vehicle. Reckless operation of motor vehicles by emotionally disturbed drivers is a major cause of traffic accidents just like alcohol, drug, and cell phone use. Emotional states such as annoyance, anger, anxiety, depression, and feeling hurried can significantly impair awareness by slowing observation and reaction times. Scents, both pleasant and unpleasant, have major effects on mood and sense of well-being. Accordingly, embodiments of the invention provide for an adaptive system which can detect a driver's mood, disperse an appropriate scent to improve the mood if it is unsafe, and learn the impact of scents on different users to effectively improve their moods.

The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as ceterizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxieity, depression, and autism. The method may include the administration of the antihistamine in combination with a stimulant medication, such as methylphenidate, thereby to achieve a synergistic effect. In any event, the amount of antihistamine and / or stimulant is effective to downregulate neurotrophic factors such as nerve growth factor or CD40. The invention is also directed to a method of preventing the onset of behavior disorders in patients presenting with symptoms of allergic rhinitis.

Novel cysteine prodrugs and their use in the treatment of diseases and / or conditions, including but not limited to diseases and / or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

The present application provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PITX1 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PITX1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.

The present invention relates to 2-Aminoquinoline derivatives of general formula Iand pharmaceutically-acceptable acid-addition salts thereof, wherein R1, R2 and X are as defined in the specification. The compounds may be used as 5-HT5A receptor antagonists. The present invention relates also to processes for making such a compound and a pharmaceutical composition comprising such a compound. Compounds of the present invention are useful in the prevention and / or treatment of anxiety depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders and gastrointestinal disorders.

The invention relates to application of bifidobacterium lactis in prevention and treatment of mental disorder, the bifidobacterium lactis is bifidobacterium lactis BL-11, and the preservation number of the bifidobacterium lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The bifidobacterium lactis provided by the invention can be used for improving the intestinal permeability and reducing the levels of LPS and D-lactic acid in blood, so that the effect of preventing and treating mental disorders is achieved, and the mental disorders comprise anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette disease and Escherberg syndrome.

The invention discloses a traditional Chinese medicine composition for treating insomnia, anxiety, depression and climacteric syndrome, and a preparation method thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 200-800 parts of cornus officinalis, 200-800 parts of schisandra chinensis, 100-500 parts of spinadate seeds, 100-500 parts of radix paeoniae alba, 100-500 parts of rehmannia, 50-250 parts of lotus plumule, 100-500 parts of moutan bark, 100-400 parts of rhizoma anemarrhenae, 100-400 parts of bupleurum chinense, and 100-400 parts of fried gardenia. Due to the synergistic effect generated by the efficacy of various drugs, the traditional Chinese medicine composition in the invention has the effects of nourishing yin, tonifying kidney, clearing away heart-fire, calming nerves and soothing liver-qi stagnation, and is used for insomnia, amnesia, chest distress, palpitation, inappetence, trance, dreaminess, easiness in waking up, fatigue, irritability, dizziness and tinnitus caused by deficiency of liver-yin and kidney-yin and heart-kidney imbalance, and insomnia, dreaminess, hot flush, sweating, dizziness and tinnitus caused by climacteric syndrome, so that insomnia, anxiety, depression and climacteric syndrome are effectively treated.

The invention relates to a new curative application of a traditional Chinese medicine, in particular to the dual-cordis effect treatment of Xin Keshu as a traditional Chinese medicine. The traditional Chinese medicine has new curative application to patients accompanied with adverse moods, such as worry, depression, and the like.

The invention discloses a bifidobacterium lactis Probio-M8 capable of relieving and treating Parkinson disease and application thereof. According to the invention, clinical symptom investigation, constipation condition investigation, treatment satisfaction and continuous medicine taking possibility comprehensive evaluation of people finally show that by taking the bifidobacterium lactis Probio-M8while the Parkinson disease treatment medicines medopa and pramipexole are taken, anxiety and depressive emotion of a patient can be obviously reduced, the sleep quality of the patient is improved, the constipation degree of the patient is alleviated, the feces hardness degree, defecation strength and endless defecation feeling are reduced, feces characters are improved, the number of times of spontaneous defecation and the number of times of complete defecation every week are increased, and finally the treatment satisfaction degree and the possibility of continuous medicine taking of the patient are improved, therefore the effects of relieving and treating Parkinson disease, anxiety and constipation are achieved.

The invention relates to the field of medicines, and particularly relates to a composition capable of regulating mood. The composition is prepared from lactobacillus helveticus R52, bifidobacterium longum R175, fructooligosaccharide, galacto oligosaccharide and xylo-oligosaccharide. The composition capable of regulating the mood provided by the invention has the characteristics of mildness and noside effects, and moreover, negative mood such as anxiety, depression, irritability and restlessness can be regulated, and symptoms of patients suffering from depression and anxiety can be effectivelyimproved.

The invention relates to a medicine for treating anxiety and depressive disorder, which is prepared by the following crude medicines according to parts by weight: 6-20 parts of radix bupleuri, 6-20 parts of radix paeoniae alba and 6-15 parts of white atractylodes rhizome; and the medicine further comprises 6-15 parts of selfheal, 3-6 parts of coptis chinensis and 3-6 parts of cinnamon. The invention further provides an application of the medicine in preparing medicine for treating anxiety and depressive disorder. The medicine is prepared by pure traditional Chinese medicine and based on enough traditional Chinese medicine and western medicine theories; the anxiety and depressive disorder is treated by concerning the morbidity background of the whole disease and the causa morbi and mechanism instead of being treated by the description of the disease; the curative effect is obvious by going deep into the base; the medicine has the same medicine strength as western medicine, so the medicine has no toxic or side effects; the medicine is easily accepted by sufferers; and with the advantages of less crude medicine components, easiness in obtaining, low cost and simple preparation process, the medicine can be popularized and used.

The invention discloses a treatment medicine of insomnia accompanied with anxiety and depression. The treatment medicine is prepared from the following crude drugs in parts by weight: 5 to 15 parts ofradix bupleuri, 5 to 15 parts of radix scutellariae, 2 to 10 parts of radix et rhizoma rhei, 5 to 15 parts of radix codonopsis, 5 to 15 parts of rhizoma pinelliae, 3 to 12 parts of rhizoma zingiberisrecens, 5 to 15 parts of fructus jujubae, 5 to 15 parts of cassia twig, 5 to 15 parts of poria cocos, 25 to 35 parts of oyster, 25 to 35 parts of magnetite, 8 to 18 parts of cortex albiziae, 8 to 18parts of semen raphani and 5 to 15 parts of radix polygalae. The treatment medicine disclosed by the invention has the effects of regulating yin and yang, smoothening and eliminating depression and tranquillization with heavy prescription and is mainly used for treating imbalance between yin and yang, liver depression caused fire and insomnia accompanied with phlegm heat, which are caused by exogenous and internal injuries and emotional upset; the treatment medicine has a remarkable improvement effect on accompanied anxiety and depression symptoms.

The invention relates to the field of biological detection, in particular to application of MMP19 in serum in anxiety depression. The invention provides an application of MMP19 protein or a specific antibody thereof in preparation of a product for detecting or diagnosing anxiety depression. According to the invention, serum MMP19 protein is used as a new marker for anxiety depression screening drugs and diagnosis. A kit for diagnosing the anxiety depression is prepared for the first time by aiming at the MMP19, the anxiety depression can be screened and diagnosed only by detecting the concentration of the MMP-19 in serum of a sample, the diagnosis efficiency and accuracy are improved, and an important value is provided for early diagnosis of the anxiety depression. Great help is provided for the prevention and treatment of anxiety and depression in China.

The invention discloses a method for analyzing emotion anxiety, depression and tension based on AR artificial intelligence, and the method comprises the following steps: temporary data collection, sleep data collection, sound emotion collection, sound data processing, resting test collection, deep breath data collection, motion test, and data import processing. Wherein the temporary data acquisition comprises the following steps: firstly, carrying out a five-minute resting test, recording electrocardiogram pulse wave data of a testee in a resting state by a data acquisition platform, normally breathing for 30 seconds, and then carrying out a one-minute deep breathing test. According to the method for analyzing emotion anxiety, depression and tension based on AR artificial intelligence, switching collection can be accurately conducted on static and moving physiological data, the collection accuracy is improved, emotion anxiety, depression and tension analysis is more accurately conducted, sleep data and sound emotion data of a patient can be collected, the types of analysis are increased, and the analysis of emotion anxiety, depression and tension can be more reliably carried out.

Provided is a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and / or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB1 gene of chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PRKCB1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and / or treatment of Asperse syndrome, pervasive developmental disorder, childhood disintegrate disorder, mental retardation, anxiety, depression, attention deficit hyperactive disorders, speech delay or language impairment, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological disease.

This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic / antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and / or differentiating a compound's anxiolytic and / or antidepressant effects. This new animal model is especially useful in detecting and / or differentiating a compound's anxiolytic and / or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MARK1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MARKI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and / or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.

The invention relates to application of insulin-like growth factor binding protein 2 in preparation of a medicine for treating mental disorder caused by brain trauma. The IGFBP2 intervention can significantly improve anxiety and depression behaviors caused by brain trauma and cognitive function decline behaviors caused by brain trauma.

The invention relates to a formula of a milk-derived polypeptide composite protein beverage for reducing pressure and promoting sleep, and solves problems of high pressure, anxiety and insomnia of numerous people in the prior art. The formula comprises the following components in percentage by weight: 30%-40% of milk-derived polypeptide, 35%-45% of gamma-aminobutyric acid, 15%-25% of asparagus powder and 3%-7% of casein hydrolysate. According the formula, the intestines, stomach and sleep of a user are conditioned through the milk-derived polypeptide, the gamma-aminobutyric acid not only has arelieving effect on hypertension, but also inhibits neurotransmitter and relieves anxiety, depression and other emotions of people, the asparagus powder is a natural food for improving sleep and relieving pressure, and the casein hydrolysate can provide protein for the human body. The beverage can reduce generation frequency of anxiety, dysphoria and other negative emotions, a drinker is relaxedin mind and body, can well enter natural sleep, the sleep quality is improved, and the beverage has a good application prospect.

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Formula (I) Wherein Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

The invention discloses a preparation process of organic acid lithium-L-proline salt, and relates to the field of synthesis and preparation of organic lithium salt micromolecular medicines. The lithium isobutyrate-L-proline salt is prepared by adopting a single solvent method and a mixed solvent method so as to achieve the purposes of development and clinical application of new organic lithium salt. The organic acid lithium-L-proline salt has positive curative effects and prevention effects on recurrent mania and depression in bipolar affective disorder, has a unique suicide risk prevention effect, can effectively relieve anxiety, depression and other emotional abnormalities, can delay central nervous system degenerative changes, and changes the in vivo distribution defects of existing inorganic lithium salt. In addition, the purpose of modifying the physical and chemical properties of a drug can be achieved by adopting a pharmaceutical eutectic or salifying technology without changingthe public valence structure of drug molecules, the clinical dosage of the lithium salt is reduced while the curative effect of central nervous system diseases is enhanced, and the occurrence of peripheral adverse reactions is avoided.